Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Phase Distribution

Ph phase_3

33%

Ph not_applicable

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(1)

Detailed Status

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 31 (33.3%)

N/A1 (33.3%)

Trials by Status

unknown133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_3

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

NCT02493764

unknownnot_applicable

Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation

NCT01714557

completedphase_1

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

NCT00894439

Clinical Trials (3)

Showing 3 of 3 trials

NCT02493764Phase 3

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Completed

NCT01714557Not Applicable

Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation

Unknown

NCT00894439Phase 1

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3